Sanofi Holds Little Hope for Early U.S. Sale of Acomplia / Zimulti (Rimonabant)

Diet drug Acomplia / Zimulti (rimonabant) has now been taken by more than 200,000 obese and overweight patients in Europe and a handful of other countries, but Sanofi-Aventis offered no encouragement on Aug. 1 to those hoping to...

Diet Pill Acomplia Now Widely Available in Mexican Border Pharmacies

Diet drug Acomplia (rimonabant), which seems at best months away from sale in the United States, is now widely available in pharmacies just across the Mexican border.

Readers increasingly are sending us reports on their...

Sanofi Drug Hits New Hurdle With Indian Knockoffs

Aug. 9 (Bloomberg) -- Sanofi-Aventis SA's Acomplia weight- loss pill, linked to suicide, is becoming popular in generic form in India. That may end the product's chances of ever reaching the U.S., where it has been delayed...

Diet Drug Acomplia Sales Dwarfed by Initial Sales of Diet Pill alli

Just how badly sales of diet drug Acomplia (rimonabant) have been set back by Sanofi's inability to bring it to the U.S. market was dramatically illustrated July 25th when GlaxoSmithKline revealed initial launch results for...

Tacconi moves back to Merck to head investigational obesity drug

Merck has brought back consumer marketing guru Len Tacconi to serve as global brand leader for its lead investigational component for obesity, taranabant. 

Tacconi, who first joined Merck in 1996 to build its consumer...